Pharmaceutical policy in China

被引:116
作者
Sun, Qiang [1 ]
Santoro, Michael A. [2 ]
Meng, Qingyue
Liu, Caitlin
Eggleston, Karen
机构
[1] Shandong Univ, Ctr Hlth Management & Policy, Inst Med Policy, Jinan 250100, Peoples R China
[2] Rutgers Business Sch, Accounting Business Eth & Informat Syst Dept, Newark, NJ USA
关键词
D O I
10.1377/hlthaff.27.4.1042
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Contradictory goals plague China's pharmaceutical policy. The government wants to develop the domestic pharmaceutical industry and has used drug pricing to cross subsidize public hospitals. Yet the government also aims to control drug spending through price caps and profit-margin regulations to guarantee access even for poor patients. The resulting system has distorted market incentives, increased consumers' costs, and financially rewarded inappropriate prescribing, thus undermining public health. Pharmaceuticals account for about half of total health spending in China, representing 43 percent of spending per inpatient episode and 51 percent of spending per outpatient visit. Yet some essential medicines are unavailable or of questionable quality.
引用
收藏
页码:1042 / 1050
页数:9
相关论文
共 37 条
[1]  
[Anonymous], 2002, Promoting rational use of medicines: Core components
[2]  
CHEN SB, 2002, CHINA PHARM, V13, P260
[3]  
CHEN X, 2007, PHARM IND CHINA INTE, P9
[4]  
CHENG W, 2005, SHANGHAI PHARMACEUTI, V26, P533
[5]  
*CHIN HLTH EC I, 2007, CHIN HLTH ACC REP
[6]  
*CHIN NAT HLTH EC, 2006, CHIN NAT HLTH ACC RE
[7]  
*CHIN PHARM ADM AS, 2006, CHANG MECH HOSP SUPP
[8]  
DU D, 2003, J LANZHOU COMMERCIAL, V19, P98
[9]  
EGGLESTON K, CHINA LABOR IN PRESS
[10]   Health service delivery in China: A literature review [J].
Eggleston, Karen ;
Ling, Li ;
Meng Qingyue ;
Lindelow, Magnus ;
Wagstaff, Adam .
HEALTH ECONOMICS, 2008, 17 (02) :149-165